Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis
- 1 May 2003
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (5), 999-1004
- https://doi.org/10.1046/j.1538-7836.2003.00201.x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjectsEuropean Journal of Clinical Pharmacology, 2003
- Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male SubjectsThrombosis and Haemostasis, 2002
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' dataThe Lancet, 2002
- The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic EffectsThrombosis Research, 2001
- New Anticoagulant DrugsChest, 2001
- In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina PectorisArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trialThe Lancet, 1999
- Thrombin and AntithromboticsSeminars in Thrombosis and Hemostasis, 1998
- Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic EnzymesThrombosis and Haemostasis, 1998
- A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary SyndromesNew England Journal of Medicine, 1996